相关实验视频

Updated: Jul 2, 2025

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts

Published on: September 20, 2024

通过心血管和心脏代谢血清蛋白质组概况,探索类风湿性关节炎的候选生物标志物

Laura Cuesta-López¹, Alejandro Escudero-Contreras¹, Yas Hanaee^1,2

¹Rheumatology Service, Department of Medical and Surgical Sciences, Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Córdoba, Spain.

Frontiers in immunology

|February 29, 2024

概括

类风湿性关节炎 (RA) 患者心血管疾病风险增加. 这项研究确定了RA和心血管疾病的蛋白质生物标志物,并显示了甲基和托法西替尼治疗如何影响这些蛋白质.

科学领域:

蛋白质组学是指蛋白质组学
免疫学免疫学免疫学
心血管医学心血管医学

背景情况:

类风湿性关节炎 (RA) 患者面临心血管疾病 (CVD) 的风险增加,通常受治疗干预的影响.
了解RA中的心血管和心脏代谢蛋白质对识别新生物标志物和阐明相关的生物途径至关重要.

研究的目的:

在类风湿性关节炎患者中识别与心血管疾病相关的蛋白质生物标志物.
调查甲状腺和托法西提尼布治疗对RA患者蛋白质组特征的影响.
探索潜在的蛋白质标记物,预测治疗反应.

主要方法:

使用Olink技术在两个RA队列 (新诊断和已确定的疾病) 和匹配的健康捐赠者 (HD) 中对184种蛋白质的血清蛋白质分析.
在6个月内接受甲索特雷克萨特或托法西提尼布治疗的RA患者的纵向分析.
记录了临床变量,包括疾病活性评分28 (DAS28).

主要成果:

在RA患者中观察到75种蛋白质的水平升高,可能与心血管疾病有关. 在两个RA队列中,有20种蛋白质常见地发生变化,CTSL1,SORT1,SAA4,TNFRSF10A,ST6GAL1和CCL18区分RA和HDs.
甲三酸减少了13种蛋白质,托法西替尼调节了10种蛋白质,与减少的DAS28.2相关. SAA4和BNP水平预测了甲状腺素不响应,而IL6的变化表明了响应.
对托法西提尼布的治疗反应与基线LOX1和CNDP1水平以及SAA4和TIMD4的变化相关.

结论:

这项研究确定了与心血管疾病相关的RA中的关键蛋白质变化,并提出了将RA患者与健康个体区分开来的候选生物标志物.
甲基和托法西提尼布不同调节这些蛋白质水平,与与治疗反应相关的明显变化.
SAA4成为预测RA治疗反应的潜在候选生物标志物.

关键词:

奥林克·奥林克·奥林克·奥林克·奥林克·奥林克·奥林克·奥林克·奥林克·奥林克·奥林克·奥林克·奥林克生物标志物生物标志物甲基特雷克萨酸盐的使用方法接近延伸试验 (PEA)类风湿性关节炎类风湿性关节炎托法西提尼布 (tofacitinib) 是一种

更多相关视频

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay

Published on: August 8, 2013

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

相关概念视频

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...

Proteomics

Proteomics

A proteome is the entire set of proteins that a cell type produces. We can study proteomes using the knowledge of genomes because genes code for mRNAs, and the mRNAs encode proteins. Although mRNA analysis is a step in the right direction, not all mRNAs are translated into proteins.
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term...